David Anderson Named a Top Healthcare Investor of 2025 by GrowthCap

BOSTON, May 1, 2025 /PRNewswire/ — Ampersand Capital Partners, a leading private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, is pleased to announce that David Anderson, General Partner, has been named a Top Healthcare Investor of 2025 by Growth Cap.

“I have the privilege of working alongside visionary leaders and exceptional teams who are driving innovation and transforming patient care. Being named a GrowthCap Top Healthcare Investor is truly an honor, but this recognition is more a reflection of Ampersand’s collective dedication to partnering with founders and entrepreneurs to advance healthcare outcomes around the world,” said David Anderson.

This year’s awardees were selected for their deep sector expertise, leadership, and ability to navigate the ever-evolving healthcare landscape. Their areas of focus include healthcare software, medical technologies, biotechnology, healthcare services, the connected patient experience, and other related areas. In addition to their investment acumen, these investors have demonstrated an ability to provide unique strategic and/or operational insights that drive value for their portfolio companies.

Managing Partner Herb Hooper commented, “David’s ability to identify transformative opportunities and work hand-in-hand with entrepreneurs to bring bold ideas to life is helping to shape the next generation of healthcare innovation. We are proud to see David’s leadership and impact celebrated through this well-deserved recognition.”

Investors were nominated by their firms, portfolio company executives, industry peers, or other leading investors. GrowthCap undertakes a methodical and thorough evaluation process for each nominee, reviewing their investment experience, feedback from industry professionals, and overall consistency.

To see the full list of honorees and learn more about the selection criteria and methodology, please visit the GrowthCap website.

Disclaimer: This award was issued by GrowthCap on April 29, 2025, and based on the time period 3/11/2024 to 3/12/2025. Award recipients are chosen based on GrowthCap’s assessment of each nominee’s professional achievements, specifically their experience in healthcare investing and the distinct strategic or operational contributions they bring to the companies they support. Details about each nominee were gathered through nomination forms, submissions via GrowthCap’s online portal, and direct input from executives at portfolio companies and other industry professionals.

Ampersand submitted a nomination, and once selected, paid a publishing and copyright fee to GrowthCap to promote this award. The data provided in this award publication is for informational purposes only and should not be construed as investment advice, endorsement, nor recommendation. GrowthCap believes the information in this publication to be accurate but does not verify its accuracy independently and does not warrant or guarantee that it is accurate or complete. GrowthCap has no obligation to provide any updates or changes to the information. No investment decisions should be made using this information.

About Ampersand Capital Partners

Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. For additional information, visit ampersandcapital.com or follow us on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/david-anderson-named-a-top-healthcare-investor-of-2025-by-growthcap-302444093.html

SOURCE Ampersand Capital Partners

Staff

Recent Posts

Medtronic announces filing of IPO registration statement for Diabetes business, MiniMed

GALWAY, Ireland, Dec. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in…

2 hours ago

Pinealage: the app that turns strangers into meditation companions — in crowdfunding phase

This app will connect people with strangers to meditate together in the real world—an invitation…

2 hours ago

IMG Saxony-Anhalt: 2026 in Sight – Saxony-Anhalt Sets the Pace for Future Industries

Despite challenging framework conditions such as high energy prices, the international introduction of tariffs, and…

2 hours ago

Kirby Medical Center Partners with Switchboard, MD to Automate Patient Communication Workflows

ATLANTA, Dec. 19, 2025 /PRNewswire/ -- Switchboard, MD is proud to announce a new enterprise partnership with…

2 hours ago

SIERRA7 RECOGNIZED AS A 2026 ELEV8 GOVCON AWARD WINNER

MCLEAN, Va., Dec. 19, 2025 /PRNewswire/ -- Sierra7, a leader in government healthcare and technology solutions,…

2 hours ago

Medome Launch Heralds the End of Medical Misdiagnoses and Lost Lives

NEW YORK, Dec. 19, 2025 /PRNewswire/ -- Medome is the first AI technology for Personal Health…

2 hours ago